In CLL, BTK-Inhibitor Resistance Remains a Confounding Problem
Investigators say attempts to overcome mutational resistance to Bruton’s tyrosine kinase (BTK) inhibitors have had mixed results among patients who have chronic lymphocytic leukemia (CLL).
Source: ajmc.com